Proteomika will use HuCAL GOLD antibodies in its proteomics programs.

MorphoSys’ AbD Serotec business unit has received a multiple research antibody order from Proteomika. AbD Serotec reports that Proteomika is among its largest customers for custom monoclonals services.

“The fast turnaround in antibody production offered by AbD Serotec together with the high quality of the resulting antibodies will help accelerate the process of biomarker identification and validation, allowing Proteomika to bring new diagnostic and prognostic tools for human diseases to the market in the shortest possible time frame,” says Laureano Simon, CEO of Proteomika.

In addition to antigen material, Proteomika has ordered HuCAL-based research antibodies to be used against a broad range of target molecules. AbD Serotec will apply MorphoSys’ HuCAL GOLD antibody technology and the Antigen Expression System AgX.

Previous articleQuantRx and Jant Pharmacal Form Alliance to Introduce Diagnostic and Monitoring Tools
Next articleIkonisys Establishes Clinical Lab for Rare-Cell Based Tests